LUX-Lung IO: A Phase II, Open Label, Non-randomised Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Afatinib (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms LUX-Lung IO
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 03 Oct 2017 Planned End Date changed from 30 Sep 2020 to 19 Feb 2021.
- 03 Oct 2017 Planned initiation date changed from 25 Sep 2017 to 16 Oct 2017.
- 25 Jul 2017 Planned initiation date changed from 15 Aug 2017 to 25 Sep 2017.